ImmuCell Corporation Stock Price and Value Analysis

Should you buy ImmuCell Corporation stock? (NasdaqCM:ICCC). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
  • This company has stable growth.
  • This stock looks overpriced.
  • This company is not making money.
  • This company is less known than others.
  • This company pays no dividend.

Inside the ICCC Numbers

ICCC Price
(ImmuCell Corporation stock price per share)
$6.52
[?] PE Ratio versus Sector 745% higher than other Healthcare stocks
[?] PE Ratio versus Industry 196% higher than other Biotechnology stocks
[?] Free Cash Flow Jitter 19%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 17,002 shares shorted. With 5,530,874 shares available for purchase and an average trading volume over the past 10 trading days of 13,500, it would take at least 1.259 days for all of the short holders to cover their shorts.

Is ImmuCell Corporation Stock on Sale?

Based on our analysis, we believe that you should not buy ImmuCell Corporation right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ICCC Stock?

Does ImmuCell Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.